Christopher Pocock

Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia

John C. Byrd, Jennifer R. Brown, Susan O’Brien et al. · New England Journal of Medicine · 2014 · 1.6K citations · Full text

Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles

David Cunningham, Eliza A. Hawkes, Andrew Jack et al. · The Lancet · 2013 · 546 citations · Full text

Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission

Andrew H. Wei, Hartmut Döhner, Christopher Pocock et al. · New England Journal of Medicine · 2020 · 403 citations · Full text

Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial

Kirit M. Ardeshna, Wendi Qian, Paul Smith et al. · The Lancet Oncology · 2014 · 380 citations

Lymphoid Neoplasia, Watch-and-wait Approach, Medicine +4

Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial

Andrew Davies, Thomas Cummin, Sharon Barrans et al. · The Lancet Oncology · 2019 · 260 citations · Full text